CLEC10A and ovarian carcinoma: In an ovarian cancer mouse model, MGL targeting by means of glycomimetic peptides was proven to activate DCs and effector immune cells, inducing tumor protection, also in combination with immune checkpoint inhibitor (ICI) therapy [22], suggesting that the MGL–Tn ligand axis may be relevant in ovarian cancer.